Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IMNN-001 by Imunon for Epithelial Ovarian Cancer: Likelihood of Approval
IMNN-001 is under clinical development by Imunon and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...
IMNN-001 by Imunon for Endometrial Cancer: Likelihood of Approval
IMNN-001 is under clinical development by Imunon and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
IMNN-001 by Imunon for Fallopian Tube Cancer: Likelihood of Approval
IMNN-001 is under clinical development by Imunon and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...
IMNN-001 by Imunon for Adenocarcinoma: Likelihood of Approval
IMNN-001 is under clinical development by Imunon and currently in Phase II for Adenocarcinoma. According to GlobalData, Phase II drugs...
IMNN-001 by Imunon for Peritoneal Cancer: Likelihood of Approval
IMNN-001 is under clinical development by Imunon and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...
IMNN-001 by Imunon for Epithelial Tumor: Likelihood of Approval
IMNN-001 is under clinical development by Imunon and currently in Phase II for Epithelial Tumor. According to GlobalData, Phase II...
IMNN-001 by Imunon for Epithelial Ovarian Cancer: Likelihood of Approval
IMNN-001 is under clinical development by Imunon and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...